21-10-2013 - 23-10-2013 Grand Hyatt, Shanghai, China
The 2013 PharmAsia Summit will focus on new R&D and commercial models for a rapidly changing China biopharmaceutical market.
The 2013 PharmAsia Summit will focus on new R&D and commercial models for a rapidly changing China biopharmaceutical market. From the government's push for innovation to increased pricing pressure on off-patent medications to faster growth in China's second-tier markets, the biopharmaceutical market in China is undergoing fundamental changes that require new business models and new ways of thinking.
This year's summit features speakers from leading multinational and domestic pharmaceutical companies discussing new models to sustain growth via case studies, panels and keynote talks.
To kick-off the summit, we will release our second annual PharmAsia Summit Report, in collaboration with McKinsey, providing an in-depth analysis of trends critical to biopharmaceutical development and commercialization in the China market.
PharmAsia Summit 2013 keynotes include top pharma leaders from Roche, Sanofi and Cardinal Health
Featured participants include:
Ming Zhang, head of R&D China, Amgen
David Snow, president, China and Hong Kong, AstraZeneca
Jean-Christophe Pointeau, president, Bristol-Myers Squibb China
Eric Zwisler, president, Cardinal Health China
Liangshang Zhang, president of global R&D, Jiangsu Hengrui Medicine
Thad Huston, president, Xian Janssen Pharmaceutical, Johnson & Johnson
Franck Le Deu, leader of Greater China Healthcare Practice, McKinsey & Company
Sophie Kornowski-Bonnet, head of partnering, Roche Pharmaceuticals
Luke Miels, regional head, Asia Pacific, Roche Pharmaceuticals
Jean-Luc Lowinski, senior vice president Asia Region, Sanofi
Henry Sun, chief executive, Tasly Pharmaceuticals